(Reuters) -German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

Berlin: Bayer has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products ...

If approved, Eylea 8 mg would become the only anti-vascular endothelial growth factor (anti-VEGF) treatment in the EU authorized for six-month intervals for both nAMD and DME, according to Bayer ...

On the surface, macular degeneration treatment Eylea continued its juggernaut path in 2022. On Tuesday, when Bayer reported fourth quarter earnings, it showed 3.2 billion euros ($3.4 billion ...

FRANKFURT, Sept 8 (Reuters) - Bayer (BAYGn.DE), opens new tabsaid on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron (REGN.O), opens new tab, has been shown to work ...

FRANKFURT, Nov 10 (Reuters) - Bayer (BAYGn.DE), opens new tab said on Friday that the European Medicines Agency recommended approval of a higher dose version of eye drug Eylea for treatment of a ...

The treatment is delivered via ... The 8 mg product, named Eylea HD, and the 2 mg dose Eylea were developed jointly by Regeneron Pharmaceuticals and Bayer AG; the new drug earned priority review ...